Stopping treatment with the combined regimen of venetoclax, lenalidomide, and rituximab after achieving MRD negativity is feasible in patients with relapsed or refractory mantle cell lymphoma (MCL), Scandinavian researchers reported at the virtual 62nd American Society of Hematology Annual Meeting and Exposition in December.
Preliminary results for the first 22 patients enrolled in the Phase 1/2 VALERIA trial indicated that the MRD-driven three-drug regimen produced a molecular remission rate of 39% at 6 months, said lead author Mats Jerkeman, MD, PhD, of Lund University and Skane University Hospital in Lund, Sweden.
Eligible patients had relapsed or refractory MCL following at least one rituximab-containing chemotherapy regimen. MRD monitoring by patient-specific real-time quantitative polymerase chain reaction was performed every 3 months during follow-up. Patients’ median age was 71; 95% were men.
Two patients had no MCL cells in their blood or bone marrow; seven were MRD negative. The overall response rate (the primary endpoint) was 59%, with 10 complete responses, three partial responses, and two patients achieving stable disease. Two of four patients who had previously been treated with ibrutinib responded to the combination regimen.
Tags: Treatment, Refractory, Mantle Cell, Lymphoma, MRC, Drug, Regimen, Relapsed